[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:pancreatic-adenocarcinoma:programmed-cell-death-1-ligand-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Pancreatic Adenocarcinoma","Programmed Cell Death 1 Ligand 1",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05365581","A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:17:42.501124Z","2026-07-05T05:32:16.805238Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06953089","DB-1311 in Combination With BNT327 or DB-1305 in Advanced\u002FMetastatic Solid Tumors",[20],"Phase 2","2026-08-26T02:19:18.331180Z","2026-06-16T05:54:07.929157Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",[27],"Phase 1\u002FPhase 2","2026-08-26T02:19:00.742020Z","2026-06-16T05:54:07.907527Z"]